Since 2013 the CDC has listed antibiotic-resistant gonorrhea as an urgent public health threat in the United States. An executive order from the National Strategy to Combat Antibiotic-Resistant Bacteria (CARB) was created to help protect Americans against antibiotic resistance. Antibiotics have successfully treated gonorrhea for decades. However, over time the bacteria have progressively developed resistance or decreased susceptibility to almost every antibiotic used for treatment. Monotherapy with an intramuscular injection of ceftriaxone is currently the only CDC-recommended treatment regimen for gonorrhea. While alternative oral regimens exist for rectal and urogenital infections, there is no other treatment option for pharyngeal infections. Reported cases of cephalosporin resistance have occurred in Europe, Asia, Australia, and Canada. Establishing public health infrastructure and coordination with local communities is crucial for preventing an outbreak of antibiotic-resistant gonorrhea in the US.